![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 23062-06-8
2. Fasedienol
3. Aloradine
4. 4,16-androstadien-3-beta-ol
5. 4,16-androstadien-3beta-ol
6. Dtw1nj7ijh
7. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
8. Androsta-4,16-dien-3-ol, (3b)-
9. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol
10. (3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-ol
11. 4-androstadienol
12. Unii-dtw1nj7ijh
13. Fasedienol [inn]
14. Aloradine [who-dd]
15. Ph94b
16. Androsta-4,16-dien-3beta-ol
17. Schembl4075431
18. Androsta-4,16-diene-3beta-ol
19. Dtxsid901032322
20. (3b)-androsta-4,16-dien-3-ol
21. Yaa06206
22. Mfcd00271236
23. Zinc34031047
24. Akos028109412
25. As-60043
26. Androsta-4,16-dien-3-ol, (3.beta.)-
27. Hy-145567
28. Cs-0376082
29. Q20707597
Molecular Weight | 272.4 g/mol |
---|---|
Molecular Formula | C19H28O |
XLogP3 | 4.6 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 0 |
Exact Mass | 272.214015512 g/mol |
Monoisotopic Mass | 272.214015512 g/mol |
Topological Polar Surface Area | 20.2 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 476 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Intended for the acute treatment of social phobia.
Vomeropherin compounds are directly delivered to the nasal passages using either a metered nasal spray or a metered nasal aerosol. By virtue of the chemoreceptors location in the nasal passages, direct connections to the hypothalamus and limbic system and the ability of our compounds to act locally, vomeropherins do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the hypothalamus and limbic system that require access to systemic circulation and must cross the blood-brain barrier followed by uptake into the brain to exert effects.
Absorption
Absorbed following nasal administration.
There is little information available on the mechanism of action of vomeropherins. These compounds are delivered to the nasal passages and bind to chemoreceptors that in turn affect the hypothalamus and the limbic system.